Bradway joined biotech giant Amgen in 2006, becoming chief executive in 2012 and chairman a year later. During his tenure as chief executive, revenue has grown 50% to nearly $26 billion last year while the market cap more than doubled to $133 billion as of July. In recent years, Bradway has honed Amgen’s focus more on drugs to treat cancers as well as cardiovascular and inflammatory diseases. Prior to joining Amgen, Bradway spent 20 years at Morgan Stanley, rising through the ranks to become managing director at the finance firm’s London office. Bradway is also a director of Boeing Co. and chairs its finance committee.